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Abstract
Oxidative stress participates in doxorubicin (Dx)–induced cardiotoxicity. The metal complex MnDPDP and its me-
tabolite MnPLED possess SOD-mimetic activity, DPDP and PLED have, in addition, high affinity for iron. Mice were
injected intravenously with MnDPDP, DPDP, or dexrazoxane (ICRF-187). Thirty minutes later, mice were killed, the
left atria were hung in organ baths and electrically stimulated, saline or Dx was added, and the contractility was
measured for 60 minutes. In parallel experiments, 10 μM MnDPDP or MnPLED was added directly into the organ
bath. The effect of MnDPDP on antitumor activity of Dx against two human tumor xenografts (MX-1 and A2780)
was investigated. The in vitro cytotoxic activity was studied by co-incubating A2780 cells with MnDPDP, DPDP,
and/or Dx. Dx caused a marked reduction in contractile force. In vivo treatment with MnDPDP and ICRF-187 atten-
uated the negative effect of Dx. When added directly into the bath, MnDPDP did not protect, whereas MnPLED
attenuated the Dx effect by approximately 50%. MnDPDP or ICRF-187 did not interfere negatively with the anti-
tumor activity of Dx, either in vivo or in vitro. Micromolar concentrations of DPDP but not MnDPDP displayed an
in vitro cytotoxic activity against A2780 cells. The present results show that MnDPDP, after being metabolized to
MnPLED, protects against acute Dx cardiotoxicity. Both in vivo and in vitro experiments show that cardioprotection
takes place without interfering negatively with the anticancer activity of Dx. Furthermore, the results suggest that
the previously described cytotoxic in vivo activity of MnDPDP is an inherent property of DPDP.
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Introduction
The anthracycline doxorubicin (Adriamycin; Dx) is one of the best
agents for treating human hematological malignancies and solid
tumors. Its use is, however, restricted by dose-limiting cardiotoxicity
[1,2]. This problem with anthracycline-induced chronic heart failure
has lately been shown in retrospective studies to be even more serious
than previously believed. Chronic anthracycline-induced cardiotoxic-
ity is associated with a poor prognosis for the affected patients, and
their survival seems to be worse than that of patients with ischemic
cardiomyopathy. At present, there is no specific evidence-based treat-
ment of anthracycline-induced chronic heart failure [3], and for pa-
tients with end-stage heart failure, heart transplantation remains the
only option [4].
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The molecular pathogenesis of anthracycline-induced cardio-
toxicity remains controversial, although the oxidative stress–based
hypothesis involving myocardial production of reactive oxygen species
has gained the widest acceptance [2]. There is substantial evidence
that superoxide anions (·O2
−) [2,5] and iron [6] play key roles in
the underlying deleterious effects. Many years ago, Doroshow et al.
[7] suggested that cardiac tissue has weak antioxidant activity because
it more or less lacks catalase. Furthermore, they showed that Dx
selectively downregulates glutathione peroxidase. The relative defi-
ciency of cardiac antioxidant defense, includes also superoxide dis-
mutase (SOD) [7,8], which has been implicated as important in
myocardial ischemia and reperfusion [9] and in xenobiotic-induced
cardiac injury [5,10]. In fact, Dx has, for a long time, been considered
as a prototypical model for oxygen-derived free radical–mediated
cardiotoxicity [10]. The SOD mimetic AEOL 10150 was recently
shown to effectively protect cardiac function from Dx-induced oxi-
dative stress in EC-SOD knockout mice [11].
It has been known for many years that anthracycline-induced
cardiotoxicity can be reduced by simultaneous administration of
the intracellular iron chelator dexrazoxane (ICRF-187), presumably
by reducing oxidative stress, allowing maximum cumulative doses
of ICRF-187 to be doubled [12]. However, the use of ICRF-187 has
been highly restricted because of suspicion that it may also protect
cancer cells against Dx and hence reduce the anticancer efficacy.
MnDPDP (mangafodipir; Teslascan) is an approved magnetic res-
onance imaging contrast agent for use in humans that has been on the
market since 1997 but was, for commercial reasons, withdrawn in
2010. During the development of mangafodipir, it was serendipitously
discovered that it had profound antioxidant properties [13], presum-
ably through its superoxide dismutase mimetic activity and high
iron-binding capability [14–16]. Manganese dipyridoxyl ethylene-
diamine (MnPLED), a metabolite of MnDPDP, has been shown to
reduce myocardial ischemia-reperfusion injury in anesthetized pigs
[17,18]. Over the past decades, it has been demonstrated that increase
in oxidative stress, unrelated to known drug metabolism pathways, usu-
ally occurs after exposure to a series of structurally unrelated anticancer
agents, including oxaliplatin, 5-fluorouracil, and paclitaxel [19]. The
mechanism(s) of initiation of reactive oxygen production during expo-
sure by different cancer chemotherapeutic agents is, however, unclear.
Interestingly, Laurent et al. [20] and Alexandre et al. [21] have
shown both in vitro and in vivo that MnDPDP protects non–cancer
cells, like blood cells, against oxidative stress induced by oxaliplatin,
5-fluorouracil, and paclitaxel without interfering negatively with the
antitumor activity. On the contrary, MnDPDP potentiates the anti-
tumor effects of these chemotherapeutics and displays an anticancer
effect of its own. These results are of interest because they suggest that
at least some of the toxic effects of secondary reactive oxygen pro-
duction after exposure to anticancer agents can be pharmacologically
ameliorated, without diminishing the anticancer efficacy. This in-
spired James Doroshow from the National Cancer Institute to write
an editorial in the Journal of the National Cancer Institute [19] where
he suggested that MnDPDP should be tested in cancer patients.
A first small feasibility study in patients with colon cancer on
adjuvant oxaliplatin plus 5-fluorouracil (FOLFOX) chemotherapy
suggests that MnDPDP protects against the dose-limiting toxicity
of FOLFOX [22].
In the present study, the protective effect of MnDPDP against
Dx-induced cardiotoxicity was examined and compared with that
of ICRF-187. The anticancer activity of Dx in the presence of
MnDPDP was also studied both under in vivo (A2780 and MX-1
xenografts) and under in vitro (A2780 and MX-1 cells) conditions.
Materials and Methods
Animals
Male CDmice, 25 ± 5 g (Charles River, Sulzfeld, Germany, and Ry,
Denmark) were used in the experiment designed to study the cardio-
protective effects of the test substance and female CD-1 nu/nu mice
(Charles River Laboratories, Calco, Italy; aged 7 weeks at the start of
the experiment). Animals received humane care in compliance with
institutional guidelines.
Drugs and Cell Lines
Dx and ICRF-187 were from Pharmacia-UpJohn (Milan, Italy) or
Sigma (St Louis, MO) and Teslascan (ready-to-use MnDPDP formu-
lation). Teslascan, MnDPDP, DPDP, and MnPLED were provided
by Nycomed Imaging AS (Oslo Norway; now GE Healthcare).
A2780 cells (human ovarian carcinoma; European Collection of Cell
Cultures, Porton Down, United Kingdom) and MX-1 cells (human
breast carcinoma; CLS, Eppelheim, Germany) were cultured in
RPMI-1640 media or Dulbecco modified Eagle medium/HAM F-12
media (1:1), respectively, supplemented with 10% (vol/vol) fetal bovine
serum (PAA, Pasching, Austria), 2 mM L-glutamine, 100 IU/ml
penicillin, and 100 μg/ml streptomycin, at 37°C in humidified air
with 5%CO2. Cell culture media and supplements were from Invitrogen
(Paisley, United Kingdom).
In Vivo/In Vitro Cardioprotective Effects of MnDPDP
and MnPLED
Male CD mice were injected intravenously (i.v.) with various doses
of saline (controls), MnDPDP, DPDP, and ICRF-187. Thirty minutes
later, mice were killed, and the left atria were hung in 20-ml organ baths
filled with 37°C Krebs buffer and stimulated with 4-Hz, 3-millisecond
supramaximal pulses (Stimulator 215/I; HSE, March, Germany). Con-
tractions were recorded isometrically by means of conventional force
transducers (F30, HSE). After equilibration (30 minutes), saline or
120 μM Dx (dose selected from pilot experiments) was added, and
contractility was measured for 60 minutes.
In parallel experiments, MnDPDP or MnPLED at the indicated
concentrations was added directly into organ baths containing isolated
atria from untreated animals, 30 minutes before Dx addition. In sub-
sequent experiments using a simpler experimental setup containing no
reusable plastic materials, the atria displayed a much higher sensitiv-
ity against Dx; 36 μM Dx resulted in more than 70% reduction in
contractile force.
Effects of MnDPDP, MnPLED, and DPDP on the
Iron-Driven Fenton Reaction
Ferric iron in the form of FeCl3 (10 μM) was partially reduced to its
ferrous form by cysteine (100 μM) in 150 mM acetate buffer, pH 5.0.
H2O2 (100 μM) was added to initiate the production of hydroxyl
radicals (·OH), as described previously [23]. Briefly, ·OH oxidizes
H2DCF (nonfluorescent 2′,7′-dichlorodihydrofluorescein; 5μM) to
fluorescent DCF (2′,7′-dichlorofluorescein). H2DCF was obtained by
hydrolyzing its acetate ester (H2DCF-DA). Dimethyl sulfoxide (10%)
and desferrioxamine (DFO) (10 μM) were used to demonstrate the for-
mation of ·OH and the involvement of iron, respectively. MnDPDP,
MnPLED, and DPDP at various concentrations were assayed for their
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inhibitory actions on the Fenton reaction. Fluorescence was measured
in an FL600 Microplate Fluorescence reader (Bio-Tek, Winooski, VT)
at an excitation of 485 nm and emission of 530 nm.
In Vivo Antitumor Activity of Dx in the Absence and
Presence of MnDPDP or ICRF-187
Two human tumor lines A2780 and MX-1 were used. The ovarian
carcinoma A2780 has a tumor doubling time of approximately 2 days
and is sensitive to Dx (tumor volume inhibition, ~90%). The mam-
mary carcinoma MX-1 has a doubling time of approximately 5 days
and is marginally sensitive to Dx (tumor volume inhibition, ~50%).
Tumor xenograft fragments (2-3 mm in diameter) were implanted
subcutaneously in both flanks of nude mice (day 0). Therapy started
when the mean diameters of the growing tumors were 5 to 8 mm. This
was day 4 for both tumor lines.
Three injections of Dx at a dose of 7 mg/kg per injection were
given i.v. with a weekly interval. This is the maximum tolerated dose
in tumor-bearing nude mice of the strain used, taking into account late
toxicity. The test substances were given i.v. 30 minutes before each
injection of Dx. ICRF-187 was administered at a dose of 50 mg/kg
(186 μmol/kg), MnDPDP at a dose of 10 μmol/kg, and Teslascan
(ready-to-use MnDPDP formulation) at doses of 5, 10, and
20 μmol/kg. Each experimental group contained five mice.
In Vitro Cytotoxic Activity of Dx, MnDPDP, and/or DPDP
The cytotoxic activity of DPDP and MnDPDP was compared
by co-incubating A2780 and MX-1 cells with MnDPDP, DPDP,
and/or Dx. The viability of cells was measured using the methylthia-
zoletetrazolium (MTT) assay. Briefly, 8000 cells were seeded per well
on a 96-well plate and grown overnight under standard conditions.
Cells were then exposed for 48 hours to various concentrations of
MnDPDP, DPDP, and/or Dx at 37°C. The viability of the cells
was then assessed by adding 5 mg/ml MTT to a final concentration
of 0.5 mg/ml and incubating cells for a further 4 hours at 37°C. The
blue formazan that is formed by mitochondrial dehydrogenases of
viable cells was then dissolved overnight at 37°C by adding 10% SDS
and 10 mM HCl to a final concentration of 5% SDS and 5 mM
HCl. Finally, the absorbance of the solution was read at 570 nm with
a reference at 670 nm in a microplate reader (SpectraMax 340; Molec-
ular Devices, Sunnyvale, CA) connected to an Apple Macintosh com-
puter running the program Softmax Pro V1.2.0 (Molecular Devices).
Viability is expressed as percent absorbance (A570nm − A670nm) relative
to the untreated control cells.
Calculations and Analysis of Results
All values are given as arithmetic means ± SEM for in vivo/vitro
cardioprotection and in vivo tumor growth data or ±SD for in vitro
Fenton reaction and cell MTT viability data.
The contractile force during the in vitro atrium experiment is pre-
sented as the percentage (mean ± SEM) of the force generated imme-
diately before incubation with Dx (time = 0 minute). The statistical
differences between nontreated and atria pretreated with MnDPDP,
ICRF-187, or MnPLED were tested by Student’s t test.
In vitro responses of Dx, MnDPDP, and/or DPDP with regard to
viability are presented as concentration-effect curves. The biphasic
concentration-effect curve of Dx was analyzed by fitting the experi-
mental data into a biphasic sigmoidal four- parameter logistic equation
(GraphPad Prism version 5.02; GraphPad Software, La Jolla, CA).
From this analysis, the low and high pD2 values (negative log of the
concentration of Dx that produces half of its maximal inhibition in
the two phases, −logIC50) were calculated.
The tumor diameters were measured biweekly with a Vernier caliper;
volumes were calculated according to the formula (length × width2) / 2,
and tumor growth curves were constructed. Antitumor activity of Dx
was assessed as percentage tumor inhibition, according to the formula:
100 − (T /C × 100), where T is the mean tumor weight; and C , the
mean tumor weight of control mice. Student’s t test was used to test for
statistically significant difference between the groups.
Results
In Vivo/In Vitro Cardioprotective Effects of
MnDPDP and MnPLED
Table 1 shows that MnDPDP, when injected into the animal
before it is killed and before the left atria were removed and placed
in an organ bath, protects the heart muscle from the deleterious effects
of Dx. Pretreating the animals with MnDPDP at 1 and 10 μmol/kg
for 30 minutes produced approximately 40% and 50% protection,
respectively (expressed as the relative improvement in contractility
at 60 minutes compared with saline-pretreated animals). When the
dose of MnDPDP was increased to 30 μmol/kg, the protective effect
disappeared (not shown). Equimolar doses of DPDP alone provided
much less protection (5%-15%). MnDPDP, at 10 or 30 μM, when
added directly into the organ bath containing isolated atria from un-
treated animals did not protect against Dx (not shown). The reference
substance ICRF-187 also protected against Dx-induced cardiotoxicity,
although larger doses were required (93 and 186 μmol/kg, corresponding
Table 1. Effects of In Vivo Pretreatment with MnDPDP and ICRF-187 on Preservation of Contractile Force of the Isolated Mouse Atria during In Vitro Treatment with Dx.
In Vivo Saline Saline ICRF-187 (93 μmol/kg) ICRF-187 (186 μmol/kg) MnDPDP (1 μmol/kg) MnDPDP (10 μmol/kg)
In Vitro: Saline n = 4 Dx n = 9 Dx n = 3 Dx n = 3 Dx n = 3 Dx n = 3
Time (min)
10 96 ± 1 79 ± 2 96 ± 2 92 ± 2 93 ± 1 93 ± 4
20 94 ± 2 58 ± 3 88 ± 4 82 ± 2 75 ± 6 84 ± 5
30 93 ± 2 49 ± 3 73 ± 7 73 ± 2 68 ± 5 75 ± 6
40 91 ± 3 42 ± 3 68 ± 6 65 ± 4 60 ± 5 68 ± 6
50 88 ± 3 38 ± 3 62 ± 7 63 ± 4 56 ± 6 62 ± 6
60 87 ± 3 35 ± 2 58 ± 7† 60 ± 4† 54 ± 6‡ 60 ± 6†
Contractile force during the experiment is presented as the percentage (mean ± SEM) of the force generated immediately before incubation with 120 μM Dx (time = 0 minute).
†P < .001, F test followed by Student’s t test; substance/Dx versus saline/Dx.
‡P < .01, F test followed by Student’s t test; substance/Dx versus saline/Dx.
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to 25 and 50 mg/kg) compared with MnDPDP (1-10 μmol/kg). The
protective effect of ICRF-187 disappeared, like that of MnDPDP,
when the dose was further increased to 372 mg/kg (not shown), that
is, both these drugs display a bell-shaped dose-response curve.
MnPLED, when added directly into the organ baths, resulted in
protection in the first series of experiments, but this effect faded in later
experiments. In subsequent experiments using a simpler experimental
setup containing no reusable plastic materials, the atria displayed a
much higher sensitivity against Dx; 36 μM Dx resulted in more than
70% reduction in contractile force. Furthermore, under these experi-
mental conditions, 10 μMMnPLED attenuated the Dx-induced effect
by approximately 50% (P < .05), whereas MnDPDP still did not result
in any protection (Figure 1). The inconsistency between the results
in the first series of experiments and the following is probably due to
the retention of the lipophilic MnPLED to plastic holders in the organ
baths. In subsequent experiments, these holders would liberate
MnPLED in high-enough quantities to mask the effect of externally
added MnPLED. Similar problems have been reported for nitroglycerin
by Ahlner et al. [24].
Effects of MnDPDP, MnPLED, and DPDP on the
Iron-Driven Fenton Reaction
Figure 2 demonstrates that DPDP inhibited the Fenton reaction
in a concentration-dependent manner; the inhibition started at 0.1 μM
and was complete at 10 μM, that is, at an equimolar concentration of
DPDP to that of the iron concentration in the reaction mixture. The
inhibitory pattern is in accordance with the reported high-stability con-
stant of DPDP for ferric iron (logK = 33.52) [25].
The iron-chelating capacity of MnDPDP was significantly higher
than that of MnPLED. In the case of MnPLED, no inhibition was
evident up to and including a concentration of 5 μM, but at 10 μM,
the inhibition was complete. These results are surprising and in oppo-
sition to both the reported iron- and manganese-chelating capacity of
DPDP and PLED. The reported stability constants between Fe3+ and
DPDP and between Fe3+ and PLED are 33.5 and 36.9 (logK ), respec-
tively, whereas the reported stability constants between Mn2+ and
DPDP and Mn2+ and PLED are 15.1 and 12.6, respectively [25].
One would therefore expect MnPLED to have a higher affinity for
Fe3+ and to be a much better inhibitor of the iron-driven Fenton reac-
tion than MnDPDP.
In Vivo Antitumor Activity of Dx in the Absence and Presence
of MnDPDP or ICRF-187
The results of A2780 and MX-1 tumor growth are given in
Figure 3. Dx treatment resulted in a tumor weight inhibition (TWI)
of 80% in the A2780-bearing mice. No statistically significant dif-
ference in TWI was seen in any of the A2780 groups pretreated with
5 or 20 μmol/kg Teslascan or with 10 μmol/kg MnDPDP. However,
statistically significant higher TWI values (P ≤ .05) were found in
the groups pretreated with 10 μmol/kg Teslascan (TWI = 91%) or
186 μmol/kg (50 mg/kg) ICRF-187 (TWI = 89%) compared to the
group treated with Dx alone. The corresponding Dx treatment in
MX-1–bearing mice resulted in a TWI of 68%. Closely comparable
results were achieved in all other groups, except for the group pretreated
with 20 μmol/kg Teslascan where TWI was increased to 83% (P≤ .05).
In Vitro Cytotoxic Activity of Dx, MnDPDP, and/or
DPDP on A2780 and MX-1 Cells
The cytotoxic activity of Dx alone on A2780 and MX-1 cancer cells
is presented in Figure 4A. As expected, Dx-sensitive A2780 cells displayed
an approximately 100-fold higher sensitivity to Dx than the partially
Dx-sensitive MX-1 cells. It is also obvious that the concentration-
response curve for A2780 displays more than one phase. When data
from subsequent experiments in A2780 cells including some lower
Dx concentrations were fitted into a biphasic sigmoidal four parameter
logistic equation (Figure 4B), it resulted in two distinct pD2 (−logEC50)
values: 8.264 (95% confidence interval = 8.001-8.528) and 6.647 (95%
confidence interval = 6.273-7.020), respectively. Although results from
MTT tests are not necessarily obtained at steady-state conditions, in-
terestingly, the pD2 values correspond well to the previously described
different inhibitory effects of Dx on the topoisomerase II enzyme.
MnDPDP, alone or in combination with Dx at threshold concen-
trations (3 nM for A2780 and 1 μM for MX-1) and at concentrations
around half-maximal effect (30 nM for A2780 and 3 μM for MX-1),
did not have any obvious cytotoxic effects in either A2780 or MX-1
cells (Figure 5). Conversely, DPDP alone had cytotoxic effects on
A2780 but not on MX-1 cells (Figure 6). Surprisingly, neither Dx at
threshold concentrations nor at concentrations around half-maximal
Figure 1. Effects of in vitro pretreatment with MnDPDP and
MnPLED on preservation of contractile force of the isolated mouse
atria during in vitro treatment with Dx (mean ± SEM; n = 5 for Con-
trols and MnPLED and n = 3 for MnDPDP).
Figure 2. The Fenton assay in presence of various concentrations
of MnPLED, MnDPDP and DPDP (mean ± SD; n = 3).
Translational Oncology Vol. 5, No. 4, 2012 MnDPDP and Doxorubicin Cardiotoxicity Kurz et al. 255
effect revealed any additive effect to the cytotoxic effect of DPDP alone
in A2780 cells. One would expect to see a clear additive effect around
the half-maximal concentrations of these two compounds.
Furthermore, addition of DPDP close to the threshold concentra-
tion (10 μM) or the half-maximal concentration (30 μM) did not
reveal any obvious additive effect to the cytotoxic effect of Dx alone
in A2780 (Figure 7).
Discussion
The incidence of chronic anthracycline-induced cardiotoxicity and
chronic heart failure ranges from 1% to 16% within weeks to months
after anthracycline chemotherapy, and it further increases with the
length of follow-up [26]. The study by Von Hoff et al. in 1979
[27] estimated that 7% of patients develop Dx-related chronic heart
failure after a cumulative dose of 550 mg/m2, and this dose was con-
sidered for many subsequent years to be the highest recommended for
Dx and daunorubicin. However, the meta-analysis by Swain et al.
[28] published in 2003 estimated an incidence as high as 26% of
patients at risk for Dx-related chronic heart failure for a cumulative
dose of 550 mg/m2. A retrospective analysis in 2006 revealed that
compared with the expected values, 30-year childhood cancer survi-
vors had a 15-fold higher rate of heart failure, a 10-fold higher rate of
other cardiovascular diseases, and a 9-fold higher rate of stroke [29].
Despite decades of research and testing of thousands of potentially
protective agents, only one drug has been approved for use in clinical
practice: ICRF-187 [2]. Interestingly, ICRF-187 is not an outcome
Figure 3. In vivo antitumor activity of Dx in the absence and presence of MnDPDP, Teslascan (Tesla), or dexrazoxane (ICRF-187) in mice
bearing A2780 or MX-1 tumors (mean ± SEM; n = 5 in each group).
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of any sophisticated and rational drug design. Its cardioprotective
activity was discovered accidentally during its preclinical testing as a
potential anticancer drug, similar to the serendipitous discovery that
the magnetic resonance imaging contrast agent MnDPDP possesses
profound cytoprotective activity.
However, ICRF-187 is not recommended at the beginning of Dx
chemotherapy in patients with metastatic breast cancer because of
suspicion that it may reduce the anticancer effect [30,31]. This possi-
bility has been questioned [32–36], and of 16 published clinical studies,
there was only 1 study [37] showing a slightly reduced response rate but
no effect on overall survival. Nevertheless, the possibility that ICRF-187
may reduce the anticancer efficacy of anthracyclines requires attention.
It is furthermore known that both anthracyclines and ICRF-187 target
topoisomerase II, although at different sites on the enzyme [2,34,38,39].
Figure 4. The cytotoxic effect of increasing concentrations of Dx in
A2780 (A and B) and MX-1 cells (A) (mean ± SD; n = 3).
Figure 5. The cytotoxic effect of MnDPDP in A2780 (A) and MX-1
(B) cells in the absence and presence of various concentrations of
Dx (mean ± SD; n = 3).
Figure 6. The cytotoxic effect of DPDP in A2780 (A) and MX-1
(B) cells in the absence and presence of various concentrations
of Dx (mean ± SD; n = 3).
Figure 7. The cytotoxic effect of Dx in the absence and presence
of various concentrations of DPDP (mean ± SD; n = 3).
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Taking into consideration the immense problem with anthracycline
cardiotoxicity, the continuing uncertainty whether ICRF-187, the only
clinically approved drug, decreases the efficacy of Dx or not is, of
course, highly unsatisfactory. Nevertheless, the results from the present
study add to other studies, suggesting that ICRF-187 does not decrease
the efficacy of Dx.
The present results suggest that MnDPDP, like ICRF-187, protects
against Dx cardiotoxicity. The finding that in vivo administration is a
prerequisite for the cardioprotective effect of MnDPDP, but not for
its metabolite MnPLED, demonstrates that the compound must be
metabolized before becoming active, that is, MnDPDP may be acting
as a prodrug. After i.v. injection, MnDPDP is rapidly dephosphorylated
to MnPLED [40], which is a much more lipophilic compound than
MnDPDP. MnPLED can presumably cross the plasma cellular mem-
brane and exert pronounced cardioprotective effects.
The reason for the bell-shaped dose-response curve of both
MnDPDP and ICRF-187, that is, the cardioprotective effect dis-
appeared when the dose was increased, is far from obvious. Laurent
et al. [20] suggested that MnDPDP in combination with cytostatic/
cytotoxic drugs increases the intracellular level of H2O2 in normal
cells from a relatively low level to one where cell survival signals are
activated, whereas MnDPDP and cytostatic/cytotoxic drugs increase
the intracellular level of H2O2 in cancer cells from a high level to levels
where apoptosis is activated. Such a cytoprotective mechanism in nor-
mal cells may explain the bell-shaped curve. However, data from a
follow-up work by Alexandre et al. [21] did not support the suggestion
that MnDPDP potentiates cytostatic/cytotoxic drug–induced increases
in the level of H2O2 in normal cells. Although the combination pro-
foundly increased the H2O2 level in cancer cells, MnDPDP decreased
it in normal cells.
Many mechanisms have been suggested to explain the anticancer
activity of Dx and other anthracyclines [41]. However, several in vitro
mechanistic experiments reported in the literature had been per-
formed at concentrations of Dx considered to be far too high compared
with peak (Cmax) and steady-state (C ss) plasma concentrations observed
in patients after standard bolus infusions (≈5 μM and 25-250 nM,
respectively). It is therefore concluded that any study involving intact
cells exposed to more than 2 μM Dx needs a cautionary reevaluation
[42]. The present study clearly demonstrates that cytotoxic effects of
Dx are reached at concentrations between 0.3 nM and 3 μM in Dx-
sensitive A2780 cells. The concentration-response curve of Dx in
A2780 cells reveals two phases, which may correlate to inhibition
of the catalytic cycle of topoisomerase II at two different steps [39].
However, because of the non–steady-state conditions in the MTT test,
such interpretation must be made with caution.
The DNA cleavage–enhancing Dx stabilizes the DNA-enzyme com-
plex in its cleaved conformation and inhibits resealing [39,41,42], lead-
ing to DNA double-strand breaks and cell death. ICRF-187 is also a
potent topoisomerase II catalytic inhibitor [36,38,43,44], but in
contrast to the DNA cleavage-enhancing drugs, it stabilizes the DNA-
enzyme complex in a “closed clamp” conformation, rendering the
enzyme less sensitive to the cleavage enhancers [43]. Thus, it inhibits
the enzymatic activity without the induction of DNA strand breaks.
Topoisomerase II is nowadays generally recognized to be the main
cellular target of anthracyclines [2,39]. Failure to relax the super-
coiled DNA blocks DNA replication and transcription. Furthermore,
DNA strand breaks trigger the apoptosis of cancer cells, apparently
through the p53-dependent pathway. Although some older studies
have suggested that formation of reactive oxygen species and lipid
peroxidation may contribute to the anticancer effects of anthracy-
clines, more recent studies do not support this suggestion, and there
now seems to be general consensus that oxidative stress is unlikely to
contribute significantly to the antitumor activity [42].
Laurent et al. [20] and Alexandre et al. [21] have shown that
MnDPDP exerts antitumor effects in colon cancer (CT-26)–bearing
mice and profoundly potentiates the antitumor efficacy of oxaliplatin
and paclitaxel in these mice. It has in addition been demonstrated that
MnDPDP potentiates the cytotoxic effects of oxaliplatin, paclitaxel,
and 5-fluorouracil in CT-26 cells [21]. The present study demonstrates
that neither MnDPDP nor ICRF-187 interferes negatively with the
antitumor activity of Dx in A2780- andMX-1–bearing mice. Although
an improved antitumor efficacy was occasionally observed, MnDPDP
did not display such a profound potentiating effect on the antitumor
activity of Dx as that described by Laurent et al. and Alexandre et al.
for oxaliplatin and paclitaxel in CT-26–bearing mice. Furthermore, no
in vitro cytotoxic activity of MnDPDP alone or in combination with
Dx was seen in either A2780 or MX-1 cells. However, DPDP alone
displayed cytotoxic activity in A2780 cells—30 μM DPDP kills
approximately 50% of the cancer cells and 100 μM kills almost all cells
(Figure 7). DPDP had little—if any—effect on the viability ofMX-1 cells.
Interestingly, no obvious additive effect of DPDP was seen on the
cytotoxic activity of Dx over its entire concentration-effect curve in
A2780 cells. One would expect to see a rather profound additive
effect around the concentrations causing half-maximal effects of these
two compounds. A speculative and unproven explanation to this may
be that DPDP inhibits a step in the topoisomerase II catalytic cycle that
differs from the step inhibited by low (<1 μM) Dx concentrations.
However, it is still difficult to understand how “one plus one seems
to equal one” over the entire concentration range of Dx and DPDP.
Interestingly, as described above, ICRF-187 has been revealed to in-
hibit a step in the topoisomerase II catalytic cycle, which differs from
that inhibited by Dx; ICRF-187 inhibits ATP hydrolysis and reopening
of the ATPase domain, thereby trapping topological complexes with
DNA inside the enzyme [39,44]. This may render the enzyme less
sensitive to DNA cleavage enhancers such as Dx. It should, however,
be stressed that the present study does not reveal any antagonistic effect
of DPDP on the Dx activity in A2780 cells (over a wide range of con-
centrations of both agents), in a similar way as has been shown with
daunorubicin on the topoisomerase II enzyme activity [38]. Hofland
et al. [34] have shown antagonistic effects of ICRF-187 on the efficacy
of daunorubicin, both under in vitro and under in vivo conditions.
However, they did not see any antagonistic effect of ICRF-187 on
the Dx efficacy. They speculated that this difference might have been
due to longer cellular retention of Dx compared with daunorubicin.
A recent study [36] suggests that Dx as well as ICRF-187 exert both
topoisomerase II–dependent and –independent apoptopic effects.
This may, in turn, explain the lack of negative interference of ICRF-
187 on Dx-induced apoptosis.
The present study used an acute experimental mice model for eval-
uating the protective potential of MnDPDP against Dx-induced
cardiotoxicity. This may be considered as a limiting factor because
the main problem with Dx in the clinical setting is chronic heart failure
that develops weeks and months after Dx administration. In the case of
ICRF-187, however, the immediate reduction in left ventricular ejec-
tion fraction seen on Dx administration in patients is in fact considered
to be a very good indicator of the risk of developing chronic heart
failure [12]. Furthermore, both MnDPDP and the reference substance
ICRF-187 protected against Dx in the used mice model.
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In conclusion, the present results suggest that MnDPDP, presumably
after being metabolized to MnPLED, protects against acute Dx cardio-
toxicity, without any negative effect on the anticancer activity of Dx.
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